FinanceFinance in Biotech & MedTechBiotech & MedTechHealthcare ProvidersPharmaceuticals

Medtronic waited two years after FDA approval for the Medicare decision that made Symplicity pay

FDA approval or a CE mark gives you permission to sell. Payers decide how much revenue you actually get, and this article shows CFOs how to build coverage, coding and net price into a launch forecast as four separate gates.

Hospital corridor with four double doors, the first open, a catheter cart waiting at the closed second door.

An FDA approval or a CE mark gives you permission to sell a drug or device. It does not tell you who will pay for it, under which billing code, at what rate, or how much of the list price you keep after rebates. Those answers come from payers, and they set the commercial value of the product. This article's argument is simple. A launch forecast whose revenue curve starts on the approval date is forecasting the wrong event. CFOs in biotech and medtech should treat reimbursement as a series of gates, each with its own probability, date and price haircut, and revenue should only start once the last gate opens.

Medtronic's renal denervation business shows the gap. Both the Medtronic Symplicity Spyral RDN and the Recor Paradise uRDN systems were approved by the FDA in November 2023. National Medicare coverage followed much later: effective October 28th, 2025, CMS released a National Coverage Determination for renal denervation for uncontrolled hypertension, and CMS's billing guidance lists an implementation date of April 6, 2026. After that the numbers moved quickly. On its June 2026 earnings call, Medtronic (reporting its own figures) said "since the NCD, we have doubled average weekly procedure volumes. And now, Symplicity is annualizing at $100 million dollars." The product, the label and the evidence were the same throughout. The only thing that changed in those 23 months was the payer decision.

Why launch forecasts in biotech and medtech break at the payer gate

The CFO owns the launch forecast, the guidance, the cash runway and the valuation that sits on top of all three. Each one fails the same way when reimbursement is modelled as an afterthought: revenue arrives late and in smaller amounts, while SG&A arrives on schedule.

Bluebird bio is the clearest recent case. The company secured FDA approvals for three therapies in under two years, yet by late 2024, only 57 patients had started treatment across bluebird's three marketed gene therapies. Trade press put the slow uptake down to challenges in securing reimbursement from payers stemming from the therapies' high list prices. Carlyle and SK Capital bought the company for $3 a share, plus a contingent value right of $6.84 cash if the portfolio of three FDA-approved gene therapies attains more than $600 million in total sales in any 12-month period before December 2027. The buyers were not pricing regulatory risk, because all three products were already approved. They were pricing the risk that payers would not pay.

The second half of the story matters just as much. This week the renamed Genetix Biotherapeutics reported, in its own release, ~$327 million U.S. net sales in the first nine months of 2026, up ~95% year over year, and BioSpace attributes the sales to increased reimbursement for American patients. The molecules and labels are unchanged. What changed were the payer contracts, the treatment-centre throughput and the outcomes-based deals.

Those deals hit the P&L directly. Bluebird's own 10-Q explained that under an outcomes-based contract it must reserve a certain portion of revenue from each sale to account for the potential that a rebate will be owed if the pre-established outcome metric is not achieved, and that the Zynteglo contract could require us to remit up to 80% of the cost of the therapy to a payer based on patient outcomes achieved. For a finance team, that is variable consideration, a revenue-recognition constraint and a cash timing problem, all created by the payer and none by the regulator. This is why reimbursement deserves its own line in a risk-adjusted model, next to clinical and regulatory risk.

How do coverage, coding and net price turn into launch revenue?

Revenue only arrives when four conditions hold together. The patient falls within the approved label. A payer has a policy that covers that patient. The provider has a billing code that is paid at a rate that makes the prescription or procedure worth doing. And after rebates, discounts and any mandated prices, the manufacturer keeps a net price that still works. Each of these conditions has its own owner, timeline and failure mode.

Coverage: who agrees to pay, for whom

In the US, coverage is split across payers. The renal denervation NCD applies to Medicare beneficiaries enrolled in either traditional Medicare or Medicare Advantage, while commercial insurers and non-Medicare payers establish their own coverage policies for their beneficiaries. Coverage also comes with conditions. The RDN decision includes coverage with evidence development (CED) study criteria and patient, physician, and facility requirements. In practice, the number of qualified sites limits volume, even for patients who are covered.

Europe adds a layer on top of national payers. The EU HTA Regulation became applicable in January 2025 for oncology medicines and advanced therapy medicinal products. The first joint clinical assessment, published in June 2026, covered Ipsen's Ojemda, which had received conditional marketing authorization in the EU in April 2026, supported by an uncontrolled phase II clinical study. An ISPOR review of the first 18 months found heightened scrutiny of clinical evidence and increased demands on manufacturers regarding study design and comparator choice. The scope widens over time: orphan medicines in 2028 and all medicinal products from 2030. Pricing and reimbursement decisions still sit with each member state. The CE mark or EMA approval opens the door, and then 27 separate payer negotiations begin.

Coding and payment: whether the claim gets paid

Device forecasts usually go wrong at this gate. Renal denervation needed specific codes: HCPCS code C1735 for Medtronic's radiofrequency catheter, C1736 for Recor's ultrasound system, and Category III CPT codes such as 0338T for the procedure. Before the NCD, CMS gave transitional pass-through payment status to Medtronic's and Recor's devices in November 2024. That helped hospitals, but as MedTech Dive noted, national coverage was what could enable more widespread use of the products.

The rules for this gate are changing in 2026. CMS published the RAPID pathway on 11 August 2026, under which a proposed national coverage determination would issue the same day as FDA market authorisation and be finalised 60 days later for Class II devices and 90 for Class III. At the same time, CMS will pause the Transitional Coverage for Emerging Technologies (TCET) pathway for new candidates, and in vitro diagnostics are excluded outright. RAPID is still a proposal. Any device plan that assumed TCET needs to be redone, and diagnostics companies should keep planning around the Medicare Administrative Contractors (MACs).

Net price: what you keep

Drug CFOs know this gate best and still tend to model it as one percentage. Drug Channels Institute estimates that manufacturers' total gross-to-net reductions for brand-name drugs reached $416 billion in 2025, and that on average, rebates and discounts reduce the selling prices of brand-name drugs to half of their list prices. Government-set prices sit on top of the rebates. Medicare's first negotiated prices took effect on 1 January 2026, at 38 to 79 percent discounts off of list prices. A further 15 drugs follow in 2027, and the third round includes the program's first Medicare Part B products, selected on January 27, 2026 for prices effective January 1, 2028. The terminal value of any long-lived small molecule or biologic now depends on a price CMS will set years after launch.

A worked example: the four-gate waterfall

Here is a hypothetical drug, with numbers chosen only to show the arithmetic. It has 20,000 label-eligible US patients and a list price of $100,000 a year. The naive forecast assumes 15% uptake: 20,000 × 15% × $100,000 = $300m.

Now apply the gates:

  • 60% of eligible patients sit with payers that have a covering policy in year one: 12,000.
  • 70% of those clear prior authorisation and step edits: 8,400.
  • Assume the same 15% uptake: 1,260 patients.
  • Gross revenue: 1,260 × $100,000 = $126m.
  • A 45% gross-to-net discount (below DCI's industry average of roughly half): net revenue of $69.3m.

The gated forecast comes to 23% of the naive one, and the drug is the same in both. This is before any timing shift. If the main commercial payers add the drug to formulary six months after approval, year-one revenue falls again.

The four-gate rule for the whiteboard: revenue = label patients × P(covered) × P(claim paid) × uptake × net price, and it starts on the date the last gate opens. If you cannot name the payer document, the billing code and the gross-to-net assumption behind a revenue line, that line stays at zero.

When the four-gate reimbursement model helps and when it misleads

The model is most useful in three situations:

  • New-to-world procedures, where there is no code, no payer precedent and no hospital budget line yet. Renal denervation is the template.
  • High-priced one-time therapies, where outcomes-based contracts make net price uncertain at the point of sale.
  • Products likely to be selected for Medicare negotiation, where net price falls sharply in a known future year. Recent legislation also changed eligibility: the OBBA broadened the orphan exclusion to drugs designated for multiple rare diseases or conditions. For some portfolios this changes the long tail more than any formulary decision.

The model can mislead in two ways. The first is false precision too early. Before Phase 3 data, you have no basis for P(claim paid) at a single payer, and a 40-line payer grid gives the board confidence it should not have. At that stage, use three scenarios for each gate and carry them into a risk-adjusted NPV of the pipeline, not a point estimate.

The second is applying US logic to markets where coverage is effectively automatic and the constraint sits somewhere else. Germany's AMNOG system reimburses from launch, but the negotiated price replaces the launch price within months, so in Germany the price gate matters more than the coverage gate. In hospital settings paid through DRG bundles, a device can be "covered" while the hospital loses money on every case. In that situation the gate is the hospital's margin and the GPO contract, and Medicare policy matters less. Use the four gates as a checklist, and in each market apply the probability to whichever gate actually limits revenue.

What to do on Monday with your launch forecast

  • Re-date the revenue start in your current launch model to the expected coverage date for each payer segment (Medicare fee-for-service, Medicare Advantage, top commercial plans, Medicaid, and each major EU market), not the PDUFA date or the CE mark date.
  • Build a one-page gate table for each segment with five columns: decision document, decision-maker, expected date, probability, and evidence still missing. Ask market access to complete it by Friday.
  • Ask for the coding status in writing: is there an existing code, does a new one need to be created, or is it a Category III or pass-through code, and which CPT or HCPCS cycle does it depend on?
  • Break the gross-to-net line into its components (commercial rebates, Medicaid best price, 340B, copay support, outcomes-based reserves) and check each one with your revenue accounting team against the variable consideration constraint.
  • For Breakthrough-designated devices, check whether the plan assumed TCET. If it did, model RAPID and the standard NCD route as two scenarios and decide whether to comment on the August 2026 notice.
  • For oncology or ATMP assets heading to the EU, confirm the comparator in your Phase 3 design matches what the JCA scoping is likely to require. Changing it after database lock costs far more.

Medtronic and Genetix kept the same products and the same labels. Revenue followed when the payer decisions came through. Next quarter, ask your team for the date each payer gate opens, and use the latest of those dates as the start of your revenue curve.

The full course on this sector: Finance in Biotech & MedTech.

Frequently asked questions

Why is FDA approval not enough to forecast revenue for a new drug or device?

FDA approval gives permission to market, but revenue depends on payer coverage, a billing code that pays an adequate rate, and the net price after rebates. Medtronic's Symplicity renal denervation system was approved in November 2023, but Medicare national coverage only took effect in October 2025, and procedure volumes doubled after that.

How should a CFO model gross-to-net in a drug launch forecast?

A CFO should model gross-to-net as separate components rather than one percentage: commercial rebates, Medicaid best price, 340B, copay support and outcomes-based rebate reserves. Drug Channels Institute estimates that rebates and discounts cut brand-name selling prices to about half of list, and Medicare negotiated prices take 38% to 79% off list for selected drugs.

What is the CMS RAPID coverage pathway for medical devices?

RAPID is a CMS pathway proposed in August 2026 under which a proposed national coverage determination would be issued on the day of FDA market authorisation. It would be finalised 60 days later for Class II devices and 90 days later for Class III devices. CMS paused new TCET candidates at the same time and excluded in vitro diagnostics from RAPID.

Does the EU joint clinical assessment decide drug prices in Europe?

No. The EU joint clinical assessment evaluates relative clinical effectiveness and safety, but pricing and reimbursement decisions remain with each member state. It has applied to oncology medicines and ATMPs since January 2025, will extend to orphan medicines in 2028, and the first report, on Ipsen's Ojemda, showed close scrutiny of comparator choice.

Go deeper

The lessons that take this article further, free to read.

  1. 1Buyers with power: payers, GPOs, and hospital systems as gatekeepersBiotech & MedTech: how the sector works
  2. 2Evidence as currency: proving value to regulators and payersBiotech & MedTech: how the sector works
  3. 3Pricing the big three financial risks: clinical, regulatory and reimbursementFinance in biotech and medtech
  4. 4Sizing the market with TAM, SAM and SOM in biotechFinance in biotech and medtech
  5. 5Valuing pre-revenue pipelines with risk-adjusted NPVFinance in biotech and medtech

Sources

Finished reading?

Validate your read to earn XP and feed your radar.